Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma

NCT07524413 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

514

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Cancinoma (NPC)
Nasopharyngeal Cancer

Interventions

DRUG: Becotatug Vedotin
DRUG: Pucotenlimab
DRUG: Gemcitabine + cisplatin (GP)
RADIATION: intensity-modulated radiotherapy
DRUG: Cisplatin

Sponsor

Sun Yat-sen University